Market Spotlight: Overactive Bladder
|出版日期||內容資訊||英文 38 Pages
|市場焦點:膀胱過動症 Market Spotlight: Overactive Bladder|
|出版日期: 2020年08月12日||內容資訊: 英文 38 Pages||
本報告提供全球膀胱過動症 (OAB) 治療藥臨床實驗形勢與市場趨勢預測相關分析，彙整疾病概要和流行病學的預測，目前主要治療藥 (已上市/開發中產品) 和臨床實驗的進展，目前未滿足需求和未來的市場機會，臨床實驗/市場將來相關專家的見解等資訊，為您概述為以下內容。
Overactive bladder is characterized by urinary urgency, and is generally accompanied by increased voiding frequency, nocturia, and incontinence. The disease affects men and women across the world, and has an adverse effect on quality of life. Prevalence and symptom severity increase with age, and the symptoms of overactive bladder persist for years in the majority of patients. Postmenopausal status has been associated with increased risk for overactive bladder in women, while in men, the presence of prostate problems increases risk. Diseases such as depression, heart disease, arthritis, hypertension, benign prostatic hypertrophy, neurological conditions, prostatitis, mobility limitations, and recurrent urinary tract infections (UTIs) are predictors of overactive bladder in men. In women, depression, irritable bowel syndrome, neurological conditions, arthritis, sleep apnea, and recurrent UTI all have a greater possibility of being associated with overactive bladder. Furthermore, behavioral and lifestyle factors also play a role in the development of overactive bladder.
Datamonitor Healthcare estimates that in 2019, there were 545.0 million prevalent cases of overactive bladder worldwide among adults aged 20 years and older, and forecasts that number to increase to 607.6 million prevalent cases by 2028.
The approved drugs in the overactive bladder space target the calcium channel, muscarinic acetylcholine receptor, SNARE proteins, and beta-3 adrenergic receptor. The majority of these drugs are administered via the oral route, with the remainder being available in intramuscular, intravesical, intradermal, intraarticular, topical, and transdermal formulations.
The largest proportion of industry-sponsored drugs in active clinical development for overactive bladder are in Phase II, with only one drug in the NDA/BLA stage.
Therapies in development for overactive bladder focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the oral or intravesical routes, while one product is also being tested in an intramuscular formulation.
The only high-impact upcoming event for drugs in the overactive bladder space is an estimated PDUFA date for vibegron. The overall likelihood of approval of a Phase I urology-other asset is 10.2%, and the average probability a drug advances from Phase III is 75%. Drugs, on average, take 10.0 years from Phase I to approval, compared to 9.0 years in the overall urology space.
The distribution of clinical trials across Phase I-IV indicates that just over half of trials in overactive bladder have been in the early and mid-phases of development, with 54% of trials in Phase I-II, and 46% in Phase III-IV.
The US has a substantial lead in the number of overactive bladder clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
Clinical trial activity in the overactive bladder space is dominated by completed trials. Astellas has the highest number of completed clinical trials for overactive bladder, with 174 trials. Astellas also leads industry sponsors with the highest overall number of clinical trials for overactive bladder, followed by Pfizer